FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioAtla's Free Cash Flow for the
three
months ended in Dec. 2024 was $-16.78 Mil. BioAtla's Revenue for the
three
months ended in Dec. 2024 was $0.00 Mil. Therefore, BioAtla's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.
The historical rank and industry rank for BioAtla's FCF Margin % or its related term are showing as below:
BCAB'
s FCF Margin % Range Over the Past 10 Years
Min: -25255.2 Med: -653.96 Max: -214.5
Current: -653.96
During the past 7 years, the highest FCF Margin % of BioAtla was -214.50%. The lowest was -25255.20%. And the median was -653.96%.
BCAB's FCF Margin % is ranked worse than 73.02% of 1012
companies
in the Biotechnology industry
Industry Median: -131.635
vs BCAB: -653.96
BioAtla FCF Margin % Historical Data
The historical data trend for BioAtla's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioAtla's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioAtla's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioAtla's FCF Margin % distribution charts can be found below:
* The bar in red indicates where BioAtla's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioAtla FCF Margin % Related Terms
Thank you for viewing the detailed overview of BioAtla's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BCAB has been successfully added to your 